

# Arpit Rao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5136811/publications.pdf>

Version: 2024-02-01

20  
papers

335  
citations

1307594

7  
h-index

888059

17  
g-index

20  
all docs

20  
docs citations

20  
times ranked

334  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Telehealth in cancer care during COVID-19: disparities by age, race/ethnicity, and residential status. <i>Journal of Cancer Survivorship</i> , 2022, 16, 44-51.  | 2.9  | 36        |
| 2  | Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?. <i>Cancers</i> , 2022, 14, 801.  | 3.7  | 23        |
| 3  | Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS194-TPS194. | 1.6  | 2         |
| 4  | Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 287-287.  | 1.6  | 2         |
| 5  | A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1531-1539.  | 7.0  | 9         |
| 6  | Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5107-TPS5107.                | 1.6  | 1         |
| 7  | Characterization of microsatellite instability (dMMR/MSI-H) and mutational landscape in a large contemporary cohort of upper tract urothelial cancer (UTUC) patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 465-465.                            | 1.6  | 4         |
| 8  | Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5063-5063.                        | 1.6  | 1         |
| 9  | A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5043-5043.                                    | 1.6  | 0         |
| 10 | Telehealth: Reducing or increasing cancer care disparities?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1582-1582.  | 1.6  | 5         |
| 11 | Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958.                                  | 10.7 | 100       |
| 12 | Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2598-2611.                             | 4.1  | 8         |
| 13 | Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer. <i>ESMO Open</i> , 2020, 5, e000943.   | 4.5  | 2         |
| 14 | NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo. <i>Cancers</i> , 2020, 12, 2659.  | 3.7  | 54        |
| 15 | Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in , and on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2020, 8, 106-115.       | 0.4  | 2         |
| 16 | Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 309-320.                                   | 3.8  | 42        |
| 17 | Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?. <i>Annals of Translational Medicine</i> , 2019, 7, S354-S354.  | 1.7  | 4         |
| 18 | Falsely Undetectable Prostate-Specific Antigen (PSA) Due to Presence of an Inhibitory Serum Factor: A Case Report and Review of Pertinent Literature. <i>American Journal of Case Reports</i> , 2019, 20, 1248-1252.                                       | 0.8  | 1         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Survival outcomes for advanced kidney cancer patients in the era of targeted therapies. <i>Annals of Translational Medicine</i> , 2018, 6, 165-165.   | 1.7 | 38        |
| 20 | The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. <i>Expert Review of Anticancer Therapy</i> , 0, , 1-9. | 2.4 | 1         |